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ABSTRACT 
Objective: The aim of this study was to develop the diallyl disulphide (DADS) liposomal dispersion and further the dispersion was to formulate 
into gel.  
Methods: The DADS liposomal system was developed using thin film hydration method. 32 factorial design was employed to study the effect of 
various factors to obtain the optimized liposomal system. Further, it was converted to gel using suitable gelling agent. The optimized liposomal 
system and gel formulations were evaluated for various parameters. The optimized gel was evaluated for its in-vitro antifungal efficacy. The 
stability studies for gel were carried as per International conference on harmonisation (ICH) guidelines. 
Results: The optimized liposomal system was having vesicle size of 208.6 nm, % entrapment was 91.7±1.16% and loading was 11.12±0.23%. % 
drug permeation was 61.10±0.85%. The zeta potential showed moderate stability. The optimized DADS liposomal gel showed satisfactory 
results. Ex-vivo permeation studies showed that DADS liposomal gel possesses sustained release and drug retention study proved better 
retention of DADS from liposomal gel than conventional gel in skin. The stability studies showed DADS liposomal gel was stable for 30 days at 
25°C /60%RH, 40°C /75%RH and refrigeration (5±3°C). 
Conclusion:  The results from the present study show that the sustained release profile of optimized DADS liposomal gel. The retention of DADS 
from liposomal gel was more than from conventional gel which helps in better pharmacological activity with least side effects.  
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INTRODUCTION 
Garlic (Allium sativum L. fam. Alliaceae) a natural product 
used world-wide for cooking, experiences an increasing 
interest due to its well-known bioactivities in the latest 
research. Epidemiological studies have shown that the 
enhanced dietary intake of garlic could reduce the incidence 
of various types of tumors such as colon, breast, lung, 
prostate, and stomach. The unique flavour and biological 
effects of garlic are generally attributed to its characteristic 
organosulfur components, which are released from garlic upon their processing (mincing, chewing and etc.). The γ-
glutamyl-S-alk(en)yl-L-cysteines are the primary sulfur 
compounds in the intact garlic, which can be hydrolysed and 
oxidized to yield S-alkyl(en)yl-L-cysteine sulfoxide (alliin). 
Alliin could be transformed to allicin when chewing or 
cutting, which activates the enzyme allinase. Allicin is highly 
unstable and instantly decompose to form various oil-soluble 
compounds involving diallyl sulfide (DAS), diallyl disulfide 
(DADS), diallyl trisulfide (DATS), vinyl dithiin and ajoene if 
conditions are appropriate. Various pharmacological actions 
includes, inhibit cell division, induce apoptosis, block 
carcinogen activation, enhance DNA repair, induce 
detoxifying enzymes (anticarcinogenic/ antimutagentic), 
inhibit microbiological growth as antibiotics antimicrobial 
(antifungal, antiviral, antibacterial), scavenge oxidizing 
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agents, induce SOD, GPx, GST, catalase (Anti-oxidant), 
increase pro-inflammatory cytokine release, stimulate 
natural killer cells (immunomodulatory), inhibit enzymes in 
cholesterol and fatty acid synthesis (anti-hypolipidemic), 
inhibit cholesterol synthesis, enhance cholesterol turnover 
(anti-hypocholesterolemic), inhibit angiotensin II, induce NO 
and H2S, cause vasodilation (anti-hypertensive), stimulate 
insulin production, interfere glucose absorption (anti-
diabetic), reduce trombosane formation, change platelet 
membrane (anti-thrombotic) and increase GSH levels by 
induction of GST (hepatoprotective)1,2. This work aimed to 
study the effects of various formulation parameters on the 
formation of DADS loaded liposomes, liposomal gel, as well 
as the evaluation of the characteristics of particles 
distribution and the DADS concentration in liposomal 
system. Meanwhile, antifungal activity of DADS liposomal gel 
in in-vitro against Candida albicans was researched. 
MATERIALS AND METHODS 
Materials 
Diallyl disulphide (DADS) was the gift sample from Synthite 
Industries Ltd., Mumbai. Phosphatidylcholine (Leciva S 70) 
was the gift sample from VAV Life sciences, Mumbai. 
Phosphatidylcholine (Phospholipon 80H) samples were 
obtained from Lipoid, Germany. Cholesterol was purchased 
from Pallav Chemicals, Mumbai. Carbopol 970, 974 and 980 
from Corel Pharma Pvt Ltd., Mumbai. All the other chemicals 
and solvents used in the experiments were of analytical 
grade. 
Methods 
Part 1: Formulation development of DADS loaded 
liposomes 
Preparation of DADS loaded liposomes 
The DADS liposomal system was prepared by thin film 
hydration method3-6. Briefly, molar solutions of various 
components were prepared in chloroform containing 0.01 
%w/w of butylated hydroxyl toluene. These molar solutions 
were added to round bottom flask with suitable glass beads 
in appropriate molar ratio. Chloroform was evaporated 
under vacuum on a rotary evaporator (JSGW equipments, 
India) at 60 ℃ (above the gel-to-liquid crystalline phase 
transition temperature of the phospholipids) to form a thin 
film on the inner surface of the round bottom flask. The dry 
lipid film was hydrated with addition of distilled water 
which was at a temperature of 60 ± 2 °C. The flask was 
shaken for 10 mins until a homogenous dispersion was 
obtained. The dispersion was subjected to probe sonication 
(Oscar ultrasonic Co. Ltd., India) at 90 W for 10 mins and was 
stored at 4 °C. In case of blank liposome, the same procedure 
was performed without the addition of DADS. 
Optimization of DADS loaded liposomes 
The effect of formulation variables (lipid film thickness, 
volume of hydration medium, lipid composition, cholesterol 
percent and DADS concentration) on the responses (EE and 
drug release) were statistically evaluated by applying one-
way ANOVA using the software package DesignExpert® 
version 9.0.3. (Stat-Ease Inc., Minneapolis, MN, USA). 
Considering the above mentioned factors the concentration 
of cholesterol and drug (DADS) were selected for 
optimization keeping volume of hydration medium, 
temperature, vacuum, cycle time of sonication etc. constant. 
It has been reported that cholesterol provides rigidity to the 
liposome membrane and hence variation in its concentration 
will ultimately result in drug leakage. The main objective of 
32 factorial design was to optimize the DADS loaded 
liposomes with maximum EE and with minimum particle 
size distribution7,8. A 2-factor 3-level full factorial design (32) 
was used for the formulation and optimization of liposomes 
by studying the influence of the two independent variables 
on the responses (Y1 and Y2) i.e. minimum particle size and 
percentage drug entrapment. The independent variables 
used were cholesterol:phospholipid (Chol:PL) molar ratio 
(X1=A) and amount of DADS added (X2=B). Each 
independent variable was kept at three levels viz. low level (-
1), medium level (0) and high level (+1) as mentioned in 
table 1. Experimental trials were carried out at all nine 
possible combinations as mentioned in table 2. 
 
Table 1: Variables and their levels in full factorial design used for optimization 
Levels  
(Code value) 
Actual values Response 
X1 
Molar ratio of 
Chol:PL 
X2 
Amount of DADS 
(mg) 
Y1 Y2 
Low (-1) 1:6 50 
Particle size (nm) % EE Intermediate(0) 1:4 70 
High(+1) 1:2 90 
 
Table 2: Possible combinations of 32 factorial design 
Runs 
Batch Code 
X1 
Molar ratio of       Chol:PL 
X2 
Amount of DADS (mg) 
Leciva S70 Phospholipon 80 H Coded Actual Coded Actual 
1 LF1 PF1 -1 1:6 -1 50 
2 LF2 PF2 -1 1:6 0 70 
3 LF3 PF3 -1 1:6 +1 90 
4 LF4 PF4 0 1:4 -1 50 
5 LF5 PF5 0 1:4 0 70 
6 LF6 PF6 0 1:4 +1 90 
7 LF7 PF7 +1 1:2 -1 50 
8 LF8 PF8 +1 1:2 0 70 
9 LF9 PF9 +1 1:2 +1 90 
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Statistical analysis of data was carried out using analysis of 
variance (ANOVA). The statistical analysis was conducted 
using Design-Expert® version 9.0.3 trial (Stat-Ease Inc., 
Minneapolis, MN, USA). The software performs response 
surface methodology (RSM) which includes the multiple 
regression analysis (MRA), ANOVA and statistical 
optimization. RSM helps to quantify the relationship 
between one or more measured response and the vital input 
factors. It helps in determination of desirable location in the 
design space. This space could be maximum, minimum or an 
area where the response is stable over a range of factor. 
Statistical relationship in the form of equations was obtained 
which shows the effect of varying A and B on the dependent 
variables, Y1 and Y2. In addition, contour and 3D surface 
plots were obtained by Design-Expert, to represent the effect 
of the independent variables graphically. To determine the 
optimal batch, the fitted mathematical model was put in use. 
The two equations derived i.e. for %EE (Y2) and minimum 
particle size (Y1) in terms of X1 (molar ratio of Chol:PL) and 
X2 (amount of DADS) were sequentially employed. 
Experimental trials were carried out in triplicates. Specific 
desired values of both the responses were assigned. The 
formulation with the desirability value closer to unity is 
chosen as the optimized formulation. For the present study, 
the criteria for optimum batch were decided as the one 
which shows minimum particle size and maximum EE. 
Characterization and evaluation of DADS loaded 
liposomes 
Entrapment efficiency (EE) and drug loading (DL) 
The EE of DADS loaded liposomal system was determined by 
indirect method9 wherein the amount of unincorporated 
DADS was determined. 2 ml of DADS loaded liposomal 
dispersion was subjected to centrifugation at 14,000 rpm for 
1 hr. The supernatant (1 ml) of the dispersion was 
appropriately diluted with methanol and the amount of the 
drug present was analysed using UV-Visible 
spectrophotometer (Shimadzu 1800) at 207 nm against 
methanol as blank. EE and DL were calculated by using 
below mentioned formulae,                                                                                     
 
Where, Wt-total amount of DADS added to the system, Wa-
amount of DADS quantified by indirect method, Wl-amount 
of lipid. 
Vesicle size, size distribution and zeta potential 
DADS liposomal dispersion was measured for vesicle size 
and extent of size distribution using malvern zetasizer ZS90 
(Malvern Instruments, UK) at a 90 degree scattering angle 
using dynamic light scattering. This technique measures the 
diffusion of particles moving under brownian motion and 
converts this to size and a size distribution using the stokes-
einstein relationship10. For light scattering measurements, 
the samples were measured at a fixed angle of 90° at 25 °C. 
The scattering intensity was adjusted between 100-500 kcps 
by appropriately diluting the liposomal dispersion with 
double distilled water. Zeta potential was measured using 
laser doppler micro-electrophoresis method by malvern 
zetasizer ZS90 (Malvern Instruments, UK) 10. Zeta potential 
was measured by filling the samples in disposable zeta cell 
cuvettes and placing it in the sample chamber of ZS 90. 
In-vitro drug permeation studies 
In-vitro drug permeation studies were carried out for both 
DADS loaded liposomal dispersion and conventional DADS 
dispersion using franz diffusion cells with an effective 
diffusion area of 3.4619 cm2 and a receiver volume of 20 ml. 
Dialysis membrane having molecular cut-off of 12-14 kDa 
was used which was previously soaked in the receptor 
medium for 24 hrs for hydration. The Receptor chamber was 
filled with phosphate buffer pH 6.8 and co-solvent methanol 
40 %v/v. The diffusion cells were maintained at 37 ± 0.1 °C 
using a re-circulating water bath and the medium in the 
receptor chambers were stirred continuously with a 
magnetic bar at 50 rpm. The membranes were initially left in 
the diffusion cells for 30 mins in order to facilitate hydration. 
1 gm of the liposome dispersion was gently placed onto 
membrane surface at the donor compartment. An aliquot of 
2 ml of samples were withdrawn at definite time intervals (1, 
2, 3, 4, 5, 6, 7 and 8 hrs) and replaced with the same amount 
of receptor medium to maintain sink condition. 
Concentration of drug permeated was determined using UV-
Visible spectrophotometer (Shimadzu 1800) at 207 nm11. 
Scanning electron microscopy (SEM) 
Surface morphology of the DADS loaded liposomal 
dispersion was characterized by SEM12,13. Small amount of 
liposomal dispersion sample was mounted on an aluminum 
stub with double sided adhesive tape. The tape was firmly 
attached to the stub and sample was scattered carefully over 
its surface. The stub with the sample was then sputter coated 
with a thin layer of gold in HUS–5GB vacuum evaporator to 
make the sample conductive, and then the sample was 
observed in Quanta 200 ESEM at an acceleration voltage of 
10 KV and processed sample was subjected to SEM analysis 
at various magnifications. 
Part 2: Formulation development of DADS liposomal gel 
The DADS loaded liposomal dispersion possesses low 
viscosity and hence it is inconvenient for topical application. 
Gel formulation is normally preferred because of their 
controlled release characteristics, improved targeting to the 
affected epidermis and optimal tissue compatibility. In 
addition, aqueous dispersions of liposomes are basically not 
stable for longer time. After optimization, DADS loaded 
liposomal system was incorporated in the gel formulation for 
further studies. Gelling agents like carbopol grades 971, 974 
and 980 were studied in varying concentrations that ranges 
from 0.5 % to 2 %w/w. Gelling agent was dispersed in 
distilled water by stirring using a magnetic bead at 100 rpm 
for 60 mins on the magnetic shaker. Propylene glycol was 
added in the above solution and then triethanolamine was 
added in a drop wise manner with continuous stirring to 
form a transparent gel. Mixing was continued until a 
transparent gel appeared, while the amount of 
triethanolamine was adjusted to achieve a gel with pH 7.014. 
DADS loaded liposomal dispersion of 10 ml contains DADS 
equivalent to 90 mg of which 6.6 ml containing 60 mg of 
DADS was blended homogenously with 3.4 gm of gel which 
was previously prepared by dissolving carbopol 980 
containing optimum concentration of gelling agent. The 
blending of DADS loaded liposomal dispersion and gel base 
made final formulation of 10 gm liposomal gel. For 
developing the optimized gel formulation various gelling 
agents and their concentrations were screened as mentioned 
in table 3. 
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Table 3: Screening and selection for optimum gelling agent grade and its concentration 
Screen of gelling agents 
Gelling agent Grade Concentration (%w/w) Consistency 
Carbopol 
971 
0.5, 1.0, 2.0 
Air entrapment 
974 Less viscous, string formation 
980 Smooth and viscous 
Screening of gelling agent concentrations 
Composition %w/w 
Formulation LG01 LG02 LG03 
Carbopol 980 0.50 1.00 2.00 
Propylene glycol 1.00 1.00 1.00 
Methyl paraben 0.18 0.18 0.18 
Propyl paraben 0.02 0.02 0.02 
Triethanolamine q.s q.s q.s 
Purified water 8.30 7.80 6.80 
 
Evaluation of DADS liposomal gel 
Appearance, consistency and pH  
DADS liposomal gel was evaluated for its appearance by 
visual inspection and examined for their consistency. For pH, 
1 gm of DADS liposomal gel sample was mixed with 9 ml of 
purified water and the pH of the resulting mixture was 
determined with a glass electrode instrument. 
Extrudability 
Collapsible aluminum tubes were filled with DADS liposomal 
gel formulation and crimped. The gel was extruded by 
applying pressure from the crimped end towards the mouth. 
The gel thus extruded was evaluated and graded. 
Viscosity 
The viscosity of the DADS liposomal gel was determined by 
brookfield digital viscometer, using spindle S96 (T shaped 
spindle) rotated at 2 rpm. The viscosity was measured at 2 
rpm after 30 secs at 25 °C. 
Spreadability 
Glass slab apparatus was used to determine the spreadability 
of DADS liposomal gel formulation. The apparatus consists of 
two glass plates (25 × 5 cm). Lower side of plate is marked 
with circle. 1 gm of DADS liposomal gel sample was placed in 
the centre of the circle. Place slowly another plain glass plate 
on the marked glass plate. The gel will spread between upper 
and lower glass plates according to its spreading capacity. 
Apply pressure of 2 kg weight on the upper plate for half an 
hour. By using scale measure the diameter of the spread gel 
on glass plate and note down the average of three readings. 
The diameter of the gel was taken as a measure of 
spreadability. 
Percent drug content  
1 gm of DADS liposomal gel formulation (equivalent to 6 mg 
of DADS) was accurately weighed and dissolved in 20 ml of 
methanol by subjecting it to bath sonication for 30 mins. The 
resulting solution was then filtered through membrane filter. 
1 ml of this filtrate is diluted with solvent mixture of 
methanol:water (5.5:4.5) to make 10 ppm of drug solution. 
Absorbance was measured at wavelength 282 nm using UV-
Visible spectrophotometer (Shimadzu 1800) and was 
compared with placebo gel which was dissolved and diluted 
to the same volume as liposomal gel formulation and 
considered as blank. 
Ex-vivo permeation studies 
Ex-vivo skin permeation studies15 were performed using 
franz diffusion cells with an effective diffusion area of 3.4619 
cm2 and a receiver volume of 20 ml. After depilation and 
washing, goat abdominal skin was excised, thoroughly 
washed with the phosphate buffer, pH 6.8 solution, dried and 
carefully cleaned of subcutaneous fat, by wiping 3 to 4 times 
with a wet cotton swab soaked in methanol and then 
preserved at freezing temperature. Before using, the skin 
was thawed, pre-hydrated for 1 hr with the phosphate 
buffer, pH 6.8 solution and then mounted between the donor 
and receptor compartments of vertical franz-type diffusion 
cell with the horny stratum corneum side layer facing the 
donor compartment and the dermal side toward the receptor 
fluid. The receptor chamber is filled with methanol: 
phosphate buffer, pH 6.8 in the ratio of 40:60. The diffusion 
cells were maintained at 37 ± 0.1 °C using a re-circulating 
water bath and the fluid in the receptor chambers were 
stirred continuously with a magnetic bar at 50 rpm. The 
membranes were initially left in the franz diffusion cells for 
30 mins in order to facilitate hydration. Care was taken to 
remove any bubbles between the underside of the diffusion 
membrane and the solution in the receiver compartment. 
Subsequently, 1 gm of the DADS liposomal gel sample was (6 
mg) gently placed onto each membrane surface at the donor 
compartment. An aliquot of 2 ml of samples were withdrawn 
from each batch at definite time intervals (1, 2, 3, 4, 5, 6, 7, 8 
hrs) and replaced with the same amount of medium to 
maintain sink condition. The amount of DADS permeated 
was monitored using UV-Visible spectrophotometer 
(Shimadzu 1800) at 207 nm. The study was conducted for 
DADS liposomal and DADS conventional gel. The permeation 
data analysis provides valuable information about the 
product behaviour in experiment since they indicate the 
amount of drug available for absorption. The cumulative 
amount of DADS permeated per unit area across excised goat 
skin as the function of time, steady state flux and 
permeability coefficient were determined. Amount of DADS 
permeated was calculated by dividing the value of 
cumulative amount of DADS released (mg) by area of 
diffusion (cm2). Permeation Profile was derived by plotting a 
graph of the amount of DADS permeated at time t (mg/cm2) 
versus time (hrs). The membrane was mounted on diffusion 
cell assembly with an effective diffusion area (orifice area) of 
3.4618 cm2. This was compared with the conventional gel. 
Following are the various permeation parameters that were 
calculated: 
A. Flux is defined as the amount of material crossing 
through a unit area of barrier or membrane in unit time 
or the permeation rate of drug at steady state. Flux or J 
ss (mg/cm2h) through the skin is calculated from the 
slope of the linear portion of plotted permeation profile 
curve. 
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B. Permeability coefficient (Kp) is the velocity of DADS 
permeation from the formulation through the 
membrane in cm/hr. It is calculated by dividing the flux 
(Jss) by initial concentration of drug (C0) in the donor 
compartment. It is dependent on the chemical structure 
of the drug, the physicochemical nature of the medium 
of application; and the physicochemical nature of the 
membrane. The unit of Kp is cm/hr.          
Determination of DADS loaded liposomal retention in 
Skin 
The ability of vesicles to help retain the DADS within the skin 
layers was investigated by determining the amount of DADS 
retained in the skin samples employed in permeation 
studies16,17. After completion of the permeation experiment, 
skin mounted on the diffusion cell was removed. The 
remaining formulation adhering to the skin was scraped 
with a spatula. The formulation applied on skin surface was 
swabbed first with phosphate buffer, pH 6.8 and then gently 
dried by pressing between two tissue papers to remove any 
adhering formulation. The skin was then perforated and cut 
into small pieces. 20 ml of methanol was added to the 
mashed mass and mechanically shaken in a water shaker 
bath at 37 ºC for 1 hr for the complete extraction of the 
DADS. The resulting solution containing strips of membrane 
was filtered and strained. The filtrate was removed, suitably 
diluted and the drug content in filtrate was determined at 
207 nm, using a UV-Visible spectrophotometer (Shimadzu 
1800). This study was performed with DADS liposomal gel 
and conventional gel. 
In-vitro antifungal activity of DADS liposomal gel 
Inoculum was prepared by dissolving (with heating) 28 gm 
of prepared medium in 1000 ml distilled water and boiled to 
dissolve completely. The microorganisms (Candida albicans) 
were streaked under aseptic conditions, and the slants were 
incubated at 37 ± 1 ºC for 24 hrs. These 24 hrs cultures were 
used for preparation of inoculum. The suspension of the 
microorganisms was prepared in 10 ml of sterile water and 1 
ml of this suspension was added to 100 ml of the nutrient 
agar medium. Cultural medium was prepared by dissolving 
(with heating) 16.25 gm of sabouraud dextrose agar in 250 
ml of purified water. The dissolved broth is sterilized for 15 
mins at 121 °C at 15 lb pressure in autoclave for about 20 
mins. The agar plate was prepared by adding sterilized 
medium and was cooled at 40 ºC. 1 ml of inoculum per 100 
ml of medium was added to the conical flask. This was 
shaken gently to avoid the formation of air bubbles and then 
transferred into petri dishes so as to obtain 6 mm thickness 
of medium. The medium in the plate was allowed to solidify 
at room temperature. The sterile borer was used to prepare 
2 cups of 6 mm diameter in the medium of each petri dish. 60 
mg of formulated liposomal and conventional DADS gel was 
placed into the bored wells of the petri-plates. The 
formulations are allowed to diffuse in the agar at the room 
temperature for an hour. The petri-plates are then incubated 
at 37 ± 2 °C for 48 hrs in the incubator. The antifungal 
activity was determined by measuring the mean diameter of 
zone of inhibition in mm after 48 hrs of incubation18.  
Stability studies 
The developed DADS liposomal gel was subjected to stability 
studies for the duration of 30 days. The optimized DADS 
liposomal gel formulation (20 gm) was filled in lacquer 
coated aluminium collapsible tubes and was stored at 
various temperature and humidity conditions 25 ± 5 °C / 60 
%RH, 40 ± 5 °C / 75 %RH and refrigeration temperature (5 ± 
3 °C) as per ICH guideline19. The samples were tested and 
evaluated initially and then at 15th and 30th day from the day 
of commencement of the study. Various parameters were 
evaluated such as appearance, consistency, pH, extrudability, 
viscosity, spreadability, percent drug content, and 
permeation studies. 
RESULTS AND DISCUSSION 
Part 01: Formulation development of DADS loaded 
liposomes 
Design Expert software performs RSM which helps to 
quantify the relationship between one or more measured 
responses and the vital input factors. It helps in 
determination of desirable location in the design space. This 
space could be maximum, minimum or an area where the 
response is constant over a range of factor. 
Optimization of formulation parameters for liposomes: 
The selected factors such as DADS concentration and molar 
ratio of Chol:PL influences the responses vesicle size and % 
EE. Table 4 and 5 shows observed responses in 32 factorial 
design for leciva S 70 and phospholipon 80H. 
 
Table 4: Observed response in 32 factorial design for leciva S 70 
Runs 
Formulation 
codes for 
Leciva  S 70 
X1 molar ratio of 
Chol:PL 
X2 amount of 
DADS (mg) 
Dependent variable 
Coded Actual Coded Actual Vesicle size (nm) % EE 
1 LF1 -1 1:6 -1 50 188.70 79.62 
2 LF2 -1 1:6 0 70 195.30 83.40 
3 LF3 -1 1:6 +1 90 208.10 91.70 
4 LF4 0 1:4 -1 50 199.81 72.80 
5 LF5 0 1:4 0 70 257.70 74.90 
6 LF6 0 1:4 +1 90 287.90 77.20 
7 LF7 +1 1:2 -1 50 201.0 68.90 
8 LF8 +1 1:2 0 70 239.20 71.60 
9 LF9 +1 1:2 +1 90 273.20 73.40 
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Table 5: Observed response in 32 factorial design for phospholipon 80H 
Runs 
Formulation 
codes for 
Phospholipon 
80H 
X1 molar ratio of 
Chol:PL 
X2 amount of 
DADS (mg) 
Dependent variable 
Coded Actual Coded Actual Vesicle size (nm) % EE 
1 PF1 -1 1:6 -1 50 190.50 68.90 
2 PF2 -1 1:6 0 70 201.30 70.50 
3 PF3 -1 1:6 +1 90 309.80 75.20 
4 PF4 0 1:4 -1 50 243.50 66.70 
5 PF5 0 1:4 0 70 298.70 65.30 
6 PF6 0 1:4 +1 90 306.80 65.10 
7 PF7 +1 1:2 -1 50 237.80 64.10 
8 PF8 +1 1:2 0 70 290.80 63.80 
9 PF9 +1 1:2 +1 90 321.40 62.00 
 
From the results of optimization studies, it was found that 
the % EE of liposomal system prepared by phospholipon 80 
H was very low. Hence. Further analysis was done for 
liposomes prepared using leciva S 70. 
For response 1: Vesicle size 
Vesicle size=285.23+20.28 × A+9.11 × B-2.60 × A × B-40.65 × 
A2-36.45 × B2  
The equation suggested that the factor A (molar ratio of 
Chol:PL) and factor B (amount of DADS) have positive effects 
on the vesicle. Positive coefficient of A term indicates that 
the vesicle size decreases with decrease in molar ratio of 
Chol:PL. Positive coefficient of B term indicate that the 
vesicle size decrease with decrease in drug concentration. 
Hence, at low level of drug concentration and low level in 
molar ratio of Chol:PL, optimum vesicle size could be 
obtained. When the coefficient values of two independent 
factors are compared, the value of coefficient of molar ratio 
of Chol:PL was found to be higher than that of DADS 
Concentration and hence, molar ratio of Chol:PL was 
considered to be a major contributing variable for vesicle 
size of liposomes. Vesicle size of DADS liposome was found 
to be from 198.7 to 315 nm range.  
Effect of Chol:PL ratio on vesicle size: Response plots as 
shown in figure 1 indicate that an optimum ratio of 1:6 
generates particles of optimum size. Increasing or decreasing 
this ratio causes changes in particle Size. The formation of 
the lipid bilayer and its fluidity is accounted by the amount 
of cholesterol inserted between the phosphatidylcholine 
molecules. Presence of cholesterol is advantageous as it 
makes the bilayer sufficiently flexible and also contributes to 
proper release of the entrapped moiety. Decreased vesicle 
size was obtained with the batches having Chol:PL ratio as 
1:6. This could be because; the addition of cholesterol in this 
ratio provides optimum rigidity to the bilayer. Decrease in 
vesicle size might be because increased amount of 
phospholipids, providing space for drug molecules to get 
entrapped.  
Effect of DADS concentration on vesicle size: The amount 
of DADS concentration will influence the vesicle size. This is 
attributed to the lipophilicity of the DADS. When the 
concentration of the DADS was increasing, vesicle size also 
increased irrespective of the ratio of the Chol:PL. 
 
 
Figure 1: 3D surface response plot for the response vesicle size 
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The relationship between the factors and the responses was 
further elucidated using response surface plots. 3D response 
surface plots in figure 1 gives a representation of the 
variations in each response when the two factors are 
simultaneously changed from lower to higher level. It gives a 
three dimensional curvature of the change in response at 
different factor levels. It also gives the variation in design 
points from the predicted response value where the desired 
working region is represented with blue colour (minimum 
particle size).  
For response 2: % EE  
% EE=74.54-6.80 × A+3.50 × B-1.89 × A × B+3.14 × A2+0.64 
× B2  
The equation suggested that the factor A have a negative 
effect on the %EE and factor B have a positive effect on the 
%EE. Negative coefficient of A term indicates that the % EE 
increase with decrease in molar ratio of Chol:PL. Positive 
coefficient of B term indicates that the %EE increases with 
increase in DADS concentration. Hence at high level of DADS 
concentration and low level of molar ratio of Chol:PL, 
increased %EE could be obtained. When the coefficient of 
two independent factors are compared, the value of 
coefficient of molar ratio of Chol:PL was found to be higher 
than that of DADS concentration and hence, molar ratio of 
Chol:PL was considered to be a major contributing variable 
for %EE of liposomes. %EE of DADS liposome was found to 
be from 68.90 - 91.70 %.  
Effect of Chol:PL ratio on %EE: Variation in the 
concentration of Chol:PL ratio extremely affects the EE, as 
illustrated in figure 2. Increase in EE at low concentration of cholesterol shows that cholesterol act as the “vesicular cement” in the molecular cavities of phospholipid bilayer and 
abolishes the gel to sol transition, forming less leaky vesicles. 
Therefore, increase in the rigidity decreases the permeability 
of the entrapped DADS and hence improves the EE. 
Effect of DADS amount on %EE: Figure 2 suggested, 
increase in concentration of DADS increases EE irrespective 
of the ratio of the Chol:PL. This is attributed to the 
lipophilicity of the DADS. Therefore, EE can be increased by 
increasing the amount of DADS added at the optimal Chol:PL 
ratio.
 
 
Figure 2: 3D Surface response plot for % EE of DADS 
Desirability and overlay plot  
The desirability plot from figure 3 suggests the region 
(working space) from which any formulation prepared 
would have results in desired range of the responses. Figure 
4 representing an overlay plot obtained by the Design 
Expert® Software is used to determine ratio of Chol:PL and 
amount of DADS, so as to have minimum vesicle size and 
maximum %EE. From overlay plot (figure 4 and table 6), 
solution 1 has desirability value closer to unity and hence 
was the best solution. The variables associated with this 
solution had same values as that of batch LF3 i.e., –1 or low 
level of Chol: PL and +1 or high level of DADS concentration 
showing vesicle size 208.1 nm and % EE as 91.70 %. Hence, 
formulation LF3 was considered as the optimized 
formulation.
 
Table 6: Solutions for optimized batch suggested by design expert 
Solution No. Chol:PL DADS concentration Vesicle size (nm) %EE 
1  -1  1  240.135  90.51  
2  -1  0.85  248.49  89.52  
3  -1  -1  216.7  79.72  
4  -1  -0.65  241.85  81.24  
5  0.96  1  198.701  73.22  
6  0.92  1  202.171  73.31  
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Figure 3: Desirability plot 
 
 
Figure 4: Overlay plot 
Composition of optimized trial: Chol:PL molar ratio= 1:6 
(0.1 M of Cholesterol and Phospholipid), DADS amount 90 
mg and final volume of formulation is 10 ml. For the present 
study, the criteria for optimum batch were decided as the 
one which shows maximum EE and minimum vesicle size. 
Based on the response surface model design batches and 
their response graphs, 6 solutions were suggested by Design 
Expert® in the table 6. From the figure 3 and 4, it is clear 
that the desirability value of solution No. 1 i.e. corresponding 
to batch LF3 is closer to unity. Hence, the formulation F3 was 
considered the optimized formulation. 
Characterization and evaluation of DADS loaded 
liposomes 
Entrapment efficiency (EE) and Drug loading (DL) 
DADS, being a lipophilic drug moiety tend to have good 
affinity towards the lipid bilayers. Thus, the preparation 
method does not have many parameters which affect the 
entrapment of the DADS. This was evident from the %EE 
which was found to be 91.7 ± 1.16 %. The drug loading was 
found to be 11.12 ± 0.23 %. 
Vesicle size, size distribution and zeta potential 
The average size was observed 208.6 nm. The liposomal 
dispersion showed polydispersity index 0.329. The result 
indicates that the liposomes were polydispersed. The 100 % 
of the vesicles were in the range of 208 nm size range as 
shown in table 7 and figure 5A. The magnitude of zeta 
potential gives a potential stability of the colloidal 
dispersion. If the particles have large positive or negative 
charge reveals that they repeal each other and there is 
dispersion stability. The liposomes in the dispersion 
exhibited zeta potential of -22.4 mV. Zeta potential of 
optimization batch is shown in figure 5B. Thus, the value of 
Zeta Potential of the formulation shows that liposome in the 
moderate stability state. 
 
Table 7: Size distribuation of DADS loaded liposomal dispersion 
Peak Size (d.nm) % Intensity PDI 
Peak 01 208.6 100.00 0.329 
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Figure 5: A. Size distribution, B. Zeta potential of DADS loaded liposomes 
 
In-vitro drug permeation studies 
The permeation of conventional DADS dispersion and DADS 
loaded in the liposomes were evaluated using vertical franz 
diffusion cells with a synthetic (cellophane) membrane 
between the donor and receptor compartments. The use of 
Franz diffusion cells provides an accurate and reliable 
method for evaluating active compound permeated from 
topical formulations. Figure 6 compares in-vitro permeation 
profile of conventional DADS dispersion and DADS loaded 
liposomal dispersion using mixture of phosphate buffer, pH 
6.8 and methanol in the ratio 60:40 as receptor medium. It 
was observed that 99.50 ± 0.34 % of DADS was permeated at 
the end of 24 hrs from conventional dispersion whereas only 
61.10 ± 0.85 % of the DADS was permeated from the 
liposomal dispersion. Rate and amount of DADS permeated 
from liposomal dispersion was lesser with initial burst 
release followed by sustained release. This can be due to 
slow diffusion of the drug through lipid matrix in the latter 
stage which may be advantageous, causing prolonged 
exposure of tumour cells to drug, increasing its clinical 
efficacy.
 
 
Figure 6: In-vitro drug permeation of DADS loaded liposomes and plain drug 
 
Scanning Electron Microscopy (SEM) 
SEM images are indicative of structure of liposome. Figure 7 indicates that developed liposomes are spherical in shape. 
 
Figure 7: SEM of DADS loaded liposomes 
Part 02: Formulation development of DADS liposomal 
gel 
Carbopol gel was quite stable and had good rheological 
properties. The liposomal dispersion was easily incorporated 
into the gel without segregation or separation of the gel and 
liposomal dispersion. The gel prepared with carbopol 974 
showed string production compared to gel prepared using 
other grades. The gel prepared using grade carbopol 971 
exhibited air entrapment relative to gel prepared using other 
grades. The carbopol 980 gel possessed optimum 
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consistency and better incorporation potential. The results 
and observations of screening and selection for various 
gelling agents. Carbopol 980 was used as a gelling agent with 
propylene glycol as the humectant. Triethanolamine was 
used as neutralising agent for the acidic polymer. The 
preservative used for the formulation were methyl paraben 
and propyl paraben. For the further incorporation of 
vesicular system, carbopol 980 was selected for further 
studies and 0.5 %w/w to 2.0 %w/w concentration range for 
the polymer was studied. 
Evaluation of DADS liposomal gel 
Appearance, consistency and pH  
The formulations prepared were translucent by nature and 
white in colour. All the three concentration of the carbopol 
980 produced the same shade of gel. The gel was examined 
for its consistency and rheological properties as mentioned 
in table 8.  
Extrudability 
The gel extrudate obtained after applying pressure at the 
crimped end towards the cap was evaluated for its ability to 
form uniform cylinder without the presence of air voids. The 
results obtained are given in table 8. 
Viscosity 
Viscosities of the formulated liposomal gels using carbopol 
980 were determined using brookfield Viscometer and the 
results were summarized in table 8. 
Spreadability 
The observations for spreadability of all formulations are 
listed in the table 8. The spreadability of the formulations is a 
characteristic derived from its more basic property i.e. 
viscosity. The greater the viscosity, the longer will be the 
time taken for spreading. The gels are expected to spread 
easily on the skin areas when applied. The spreadability also 
depends on the polymer in formulation, possessing typical 
physicochemical properties which create surface tension 
between slide and product. 
Drug content 
The drug content was found by performing the assay and the 
results found are shown below in the table 8. Based on the 
evaluation parameters, Batch LG2 was selected as the best 
batch giving the optimum results. This batch was further 
evaluated for permeation studies, drug retention studies, 
anti–fungal activity and stability studies. 
 
Table 8: Evaluation parameters of various gel formulations 
Carbopol 980 
(%w/w) 
Consistency pH 
Extrudab
ility 
Viscosity (cps) 
Spreadability 
(gm.cm/sec) 
Drug content 
(%) 
0.50 + 6.70 ± 0.05 + 127857 ± 921 5.12 ± 0.02 95.94 ± 0.32 
1.00 ++ 6.80 ± 0.03 ++ 148900 ± 586 7.78 ± 0.06 97.83 ± 0.86 
2.00 +++ 7.17 ± 0.05 +++ 186699 ± 321 5.59 ± 0.05 93.82 ± 0.41 
+=good, ++=optimum, +++=higher/harder. Date given in triplicates. 
Ex-vivo permeation studies 
The permeation studies were carried out using goat 
abdominal skin. The permeation analysis was carried out to 
compare the permeation potentials of the DADS liposomal 
gel (LG2) with conventional DADS gel. Figure 8 indicates the 
amount of drug permeated across goat abdominal skin from 
the formulations. The amount of drug permeated from the 
DADS liposomal gel (LG2) was much slower than the 
conventional DADS gel. Lower flux and permeability 
coefficient of liposomal gel is suggestive of prolonged drug 
release. Liposomal gel produced sustained release of DADS 
because of the presence of several lipid bilayer that release 
the DADS slowly over prolonged period of time. The 
cumulative amount of DADS permeated at the end of 24 hrs, 
flux and permeability coefficient were calculated for each of 
the formulations. Comparison of drug kinetic permeation 
parameters obtained provides insight to sustained drug 
permeability in DADS liposomal gel formulation. The table 9 
depicts the comparison of permeation parameters liposomal 
and conventional DADS gel formulations at the end of 24 hrs. 
 
Table 9: Drug kinetic permeation parameters 
Parameter Liposomal DADS gel Conventional DADS gel 
Amount permeated (mg) 1.7001±0.0029 2.4617±0.0093 
Flux (mg/cm2 hr) 0.05904±0.00291 0.08862±0.00197 
Permeability coefficient 0.006711±0.000075 0.008466±0.000045 
Date given in triplicates. 
 
Figure 8: Permeation Profile of conventional and liposomal (LG2) DADS gels  
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Determination of DADS loaded liposomes retention in 
Skin 
In–vitro skin deposition of DADS from both formulations was 
calculated and compared. The DADS liposomal gel and 
conventional DADS gels showed 15.30 ± 0.59 % and 9.11 ± 
0.65 % drug retained in membrane respectively. Thus, the 
amount of DADS retained in membrane was more for 
liposomal gel than conventional gel. 
In-vitro antifungal activity of DADS liposomal gel. 
The antifungal activity of DADS liposomal gel (LG2) was 
determined by measuring the diameter of inhibition zones in 
mm. The results for Candida albicans are shown in figure 9. 
The zone of inhibition was considerably larger for the 
liposomal gel (29.51 ± 3.18 mm) as compared to the 
conventional gel (13.82 ± 2.24 mm) at 0.60 % concentration 
of drug at the end of incubation. 
 
 
Figure 9: In-vitro antifungal activity against candida albicans 
Stability studies 
The stability studies of the DADS liposomal gel were carried 
out by subjecting the formulation to three conditions, at 25 
°C / 60 %RH, 40 °C / 75 %RH and refrigeration temperature 
(5 ± 3 °C). The samples were analysed at predetermined 
time points for various parameters mentioned below. All the 
parameters were in the acceptable limits (table 10, 11 and 
12) which showed that formulations were stable over the 
period of 30 days. There was no significant increase in the 
pH, drug content, viscosity and spreadability. Also the 
appearance was similar as that observed initially. The 
permeation analysis data of the formulation mentioned in 
the figure 10 suggested a constant release pattern of the 
drug thereby indicating the stability of liposomal gel. It was 
observed that the formulation was more stable when kept in 
refrigerated conditions (5 ± 3 °C) as compared to 25 °C / 60 
%RH, 40 °C / 75 %RH. Although the difference was not 
substantial. All the parameters were in the acceptable limits 
which showed that the formulation was stable over a period 
of 30 days. 
  
Table 10: Evaluation parameters of DADS liposomal gel at 25 °C /60 %RH 
Parameter 0 day 15 days 30 days 
Appearance Translucent white  Translucent white Translucent white 
Extrudability ++ ++ ++ 
Spreadability 5.78 ± 0.32 5.56 ± 0.47 5.47 ± 0.64 
pH 6.80 ± 0.18 6.70 ± 0.15 6.65 ± 0.22 
Viscosity (cps) 147012 ± 243 146919 ± 146 146901 ± 212 
Drug content (%) 97.70 ± 0.16 97.30 ± 0.11 97.10 ± 0.54 
          +=good, ++=optimum, +++=higher/harder. Date given in triplicates. 
Table 11: Evaluation parameters of DADS liposomal gel at 40 °C / 75 %RH 
Parameter 0 day 15 days 30 days 
Appearance Translucent white  Translucent white Translucent white 
Extrudability ++ ++ + 
Spreadability 5.78 ± 0.32 5.62 ± 0.55 5.587 ± 0.34 
pH 6.80 ± 0.18 6.78 ± 0.06 6.64 ± 0.08 
Viscosity (cps) 147012 ± 243 146953 ± 476 146683 ± 458 
Drug content (%) 97.70 ± 0.16 97.10 ± 0.78 96.70 ± 0.55 
          +=good, ++=optimum, +++=higher/harder. Date given in triplicates. 
Table 12: Evaluation parameters of DADS liposomal gel at refrigeration (5 ± 3 °C) 
Parameter 0 day 15 days 30 days 
Appearance Translucent white  Translucent white Translucent white 
Extrudability ++ ++ ++ 
Spreadability 5.78 ± 0.32 5.72 ± 0.09 5.72 ± 0.15 
pH 6.80 ± 0.18 6.8 ± 0.08 6.70 ± 0.09 
Viscosity (cps) 147012 ± 243 147141 ± 248 147100 ± 258 
Drug content (%) 97.70 ± 0.16 97.42 ± 0.09 97.38 ± 0.18 
          +=good, ++=optimum, +++=higher/harder. Date given in triplicates. 
0 
5 
10 
15 
20 
25 
30 
35 
Conventional DADS gel DADS loaded liposomal gel Placebo gel loaded with blank 
liposomes 
M
ea
n
 
di
am
et
er
 
(m
m
) 
Formulations 
In-vitro antifungal activity against Candida albicans 
Gupta et al                                                                                                                 Journal of Drug Delivery & Therapeutics. 2019; 9(2):105-117 
ISSN: 2250-1177                                                                                  [116]                                                                                 CODEN (USA): JDDTAO 
 
Figure 10: Permeation study of DADS liposomal gel at A. 40 ℃ /75 %RH, B. 25 ℃ / 60 %RH and C. refrigeration 
temperature (5 ± 3 ℃). 
 
Over the last several years, the frequency of life-threatening 
fungal infections has increased dramatically, particularly 
among cancer, diabetic and immunocompromised patients. 
The yeast Candida albicans is an opportunistic pathogen that 
causes life-threatening disease in immunocompromised 
mammalian hosts. In fact, candidiasis has been found to 
account for approx. 52–63 % of all nosocomial fungal 
infections. The high occurrence of candidiasis has been 
attributed, at least in part, to selective pressure induced by 
the increased use of antifungal agents18. Most of the available 
antifungal agents are plagued by dose limiting toxicity issues 
as well as other harmful effects. To make matters worse, 
many antifungal drugs are losing their effectiveness because 
of the development of drug resistance in many pathogens. 
This consequently demands an increasing dose requirement, 
which results in higher chances of toxic manifestations. A 
potential and increasingly widely accepted way to 
circumvent this problem is to turn to plant-based alternative 
therapeutics over conventional drug therapy that show 
improved antimicrobial activity and reduced toxicity. Among 
various plant products, garlic has been traditionally used in 
diet and in medicinal form for its anti-infective properties20-
22. A reported study showed that the antimicrobial activity of 
DADS is more than the other garlic components23,24.  The 
improved efficacy of liposome encapsulated DADS can be 
correlated to preferential delivery to pathogen-harbouring 
macrophages, while the free form of DADS had inadequate 
access to affected sites. Particulate formulations like 
liposomes are specifically taken up by macrophages. The 
drug-loaded macrophages further act as secondary depot for 
the drug18. The antifungal activity against candida albicans 
showed higher for DADS liposomal gel than the conventional 
gel because of longer retention of DADS in vesicular form 
which helps in more pharmacological activity over a period 
of time. The higher retention of DADS from liposomal gel 
than conventional gel helps in decreasing the dose to get 
same pharmacological effects as that of conventional 
formulations. Further, reducing the dose helps in unwanted 
pharmacological effects. In spite of the well-established role 
of DADS against both bacterial and fungal pathogens, its 
usage could not be translated into the clinical setting mostly 
because of its poor solubility. Thus the poor aqueous 
solubility of DADS hampers the development of a suitable 
dosage form that can facilitate its systemic distribution upon 
administration into the host. The problem is likely to be 
circumvented through the use of an appropriate delivery 
system, such as liposomes, that can solubilize the drug 
molecule efficiently and modify the distribution of the drug 
in the body. It is also desirable that such a novel drug 
formulation should facilitate controlled release and 
preferential delivery at the site of infection. 
CONCLUSION 
The DADS liposomal system was prepared by using thin film 
hydration method using leciva S 70 as a vesiclular 
component, cholesterol as rigidity modulator and butylated 
hydroxyl toluene as antioxidant. The liposomal system was 
optimized by using 32 full factorial design by considering the 
effect of independent variables (level of ratio of vesicle 
forming component–Chl:PL and drug) on the dependent 
variables (vesicle size and %EE). It was seen that the Chol:PL 
ratio of 1:6 and drug concentration of 90 mg showed 
maximum EE and minimum vesicle size. The optimized 
liposomal system contains 208.6 nm vesicle size and zeta 
potential value of -22.4 mV which shows moderate stability 
of system. The system contains maximum EE of 91.7 ± 1.16 
% and loading was found to be 11.12 ± 0.23 %. The in-vitro 
permeation studies showed that 99.50 ± 0.34 % of DADS was 
permeated at the end of 24 hrs from conventional dispersion 
whereas only 61.10 ± 0.85 % from liposomal system 
confirming sustained profile of DADS. In order to improve 
the stability of the liposomal system, it was incorporated into 
gel formulation. The optimized gel formulation possessing 
the satisfactory parameters. The ex-vivo permeation studies 
and drug retention studies proved longer and more 
pharmacological effects of DADS liposomal gel than the 
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conventional gel. This may result in retention of drug in skin 
layer and it will not permeate to greater extent through the 
skin thus avoiding systemic side effects. The stability studies 
proved that the formulation was stable over a period of 30 
days as per the various storage conditions mentioned by ICH. 
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